Antigen-specific cellular immunotherapy of leukemia. (Q36240201)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16121214%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

review article

1 reference

title

Antigen-specific cellular immunotherapy of leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16121214%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16121214%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Viggo Van Tendeloo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16121214%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

author name string

Van Driessche A

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16121214%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Gao L

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16121214%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Stauss HJ

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16121214%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Van Bockstaele DR

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16121214%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Berneman ZN

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16121214%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

publication date

1 November 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16121214%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16121214%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16121214%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16121214%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

page(s)

1863-1871

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16121214%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403930

6 January 2020

exact match

0 references

cites work

The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Identical-twin bone marrow transplants for leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Telomerase catalytic subunit homologs from fission yeast and human

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

The candidate Wilms' tumour gene is involved in genitourinary development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Altered expression of the WT1 wilms tumor suppressor gene in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Wilms' tumor gene (WT1) expression in lung cancer, colon cancer and glioblastoma cell lines compared to freshly isolated tumor specimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Proteinase-3, a serine protease which mediates doxorubicin-induced apoptosis in the HL-60 leukemia cell line, is downregulated in its doxorubicin-resistant variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

The phylogeny of proteinase 3/myeloblastin, the autoantigen in Wegener's granulomatosis, and myeloperoxidase as shown by immunohistochemical studies on human leukemic cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Immunotherapy with CTLs restricted by nonself MHC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Wilms' tumour gene 1 (WT1) in human neoplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Exploiting alloreactivity for tumour immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Adoptive-cell-transfer therapy for the treatment of patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Exploiting T cell receptor genes for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

An antigenic peptide produced by peptide splicing in the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Gene therapy with B7.1 and GM-CSF vaccines in a murine AML model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Immunobiology of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Dendritic cells as vectors for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Immunotherapy of cancer with dendritic-cell-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Cancer immunotherapy with mRNA-transfected dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Emerging clinical applications of RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Cancer immunotherapy using RNA-loaded dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Induction of chronic lymphocytic leukemia (CLL)–specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Ex vivo induction of viral antigen-specific CD8 T cell responses using mRNA-electroporated CD40-activated B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Dendritic cell immunotherapy: mapping the way.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Immunogenicity of WT-1 peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

7 January 2021

BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

7 January 2021

Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

7 January 2021

Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

7 January 2021

Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

7 January 2021

Expression of the Wilms' tumor gene WT1 in the murine urogenital system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

7 January 2021

In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

7 January 2021

Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

7 January 2021

Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

7 January 2021

The CD68 protein as a potential target for leukaemia-reactive CTL

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

7 January 2021

Cancer immunotherapy targeting Wilms' tumor gene WT1 product

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

7 January 2021

Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

7 January 2021

WT1-targeted immunotherapy of leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

7 January 2021

Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

7 January 2021

Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

7 January 2021

Immunotherapy of hematologic malignancy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

7 January 2021

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

7 January 2021

Dendritic cell therapy of cancer: can it fulfill its promise?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

7 January 2021

mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

7 January 2021

CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403930

7 January 2021